Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

Valent, Peter; Horny, Hans‐Peter; Bennett, John M.; Fonatsch, Christa; Germing, Ulrich; Greenberg, Peter L.; Haferlach, Torsten; Haase, Detlef; Kölb, Hans-Jochen; Krieger, O.; Loken, Michael R.; Loosdrecht, Arjan van de; Ogata, Kíyoyuki; Órfão, Alberto; Pfeilstöcker, Michael; Rüter, Björn; Sperr, Wolfgang R.; Stauder, Reinhard; Wells, Denise A.

doi:10.1016/j.leukres.2006.11.009

Cited by 447 publications

(462 citation statements)

References 55 publications

Supporting

Mentioning

422

Contrasting

Unclassified

Order By: Relevance

“…MFC is capable of identifying dysplastic features in BM samples and, thus, was supposed to be added to the diagnostic workup in patients who have suspected MDS. [13][14][15][16]32,34 In the current study, several aspects regarding the specificity and sensitivity of MFC for diagnosing MDS have been elucidated in agreement with previous studies. 15,16 In the current series and in the data reported by van de Loosdrecht et al, 16 this also is true for the identification of dysplastic features in cell lineages that were not rated dysplastic by CM alone.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Kern¹,

Haferlach²,

Schnittger³

et al. 2010

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:The diagnosis and classification of myelodysplastic syndromes (MDS) is based on cytomorphology (CM) and cytogenetics (CG). Multiparameter flow cytometry (MFC) may add important diagnostic information. METHODS: To evaluate the potential role of MFC in the diagnostic setting of MDS, the authors analyzed the results from 1013 patients with suspected MDS by using CM, CG, and MFC in parallel. RESULTS: Concordance between CM and MFC was 82% for diagnostic results in 788 patients who had unequivocal CM results. An additional 225 patients had only minor dysplastic features identified by CM, including 51 patients (22.7%) who had clear evidence of MDS by MFC. Twelve patients who had no indication of MDS identified by CM had MDS-typical CG aberrations; in 6 of those patients (50%), MFC revealed MDS characteristics. In another 11 of 23 patients (47.8%) who had minor dysplastic features identified by CM and MDS-typical CG aberrations, MFC revealed MDS characteristics. The percentages of blasts determined by CM and by MFC were strongly correlated (P < .001). The frequency of aberrantly expressed antigens differed significantly between patients rated by CM as MDS (highest frequencies), suspected MDS, and no MDS (lowest frequencies). In various patients, MFC identified MDS-typical aberrant antigen expression in cell compartments that were not rated dysplastic by CM. The numbers of aberrantly expressed antigens were correlated with International Prognostic Scoring System scores and overall survival. CONCLUSIONS: The current analysis clearly demonstrated an increased diagnostic yield with MFC when added to CM and CG in patients with suspected MDS. Cancer

show abstract

Section: Discussionsupporting

confidence: 89%

“…10,11 However, many patients who have inconclusive CM results and a normal karyotype remain 9,32,33 for whom an MDS cannot be diagnosed or ruled out. MFC is capable of identifying dysplastic features in BM samples and, thus, was supposed to be added to the diagnostic workup in patients who have suspected MDS.…”

Section: Discussionmentioning

confidence: 99%

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Kern¹,

Haferlach²,

Schnittger³

et al. 2010

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Included patients had a confirmed diagnosis of de novo MDS, based on morphologic abnormalities in the BM, cytopenia(s), and/or the presence of cytogenetic aberrations [21]. Patients were classified following FAB [1] and WHO criteria [3], excluding those with BM blasts >30% and Chronic Myelomonocytic Leukemia (CMML) with white blood cells count >12 3 10 9 /L.…”

Section: Methodsmentioning

confidence: 99%

Myelodysplastic syndromes in South America: A multinational study of 1080 patients

et al. 2015

View full text Add to dashboard Cite

There are previously reported data describing differences between Asian and European patients with Myelodysplastic Syndromes (MDS), few direct comparisons based on cancer registration characteristics or using cohorts to validate scoring systems. This is the first study from South-America, which attempts to describe demographic, clinical features, and outcome of MDS patients. We retrospectively analyzed 1,080 patients with de novo MDS from Argentina (635), Brazil (345), and Chile (100). Chilean patients were younger (P 5 0.001) with female preponderance (P 5 0.071). Brazilian series showed a higher predominance of RARS subtype regarding FAB and WHO classifications (P < 0.001). Hemoglobin levels were significantly lower in Brazilian and Chilean series (P < 0.001), and Chilean series also showed a lower platelet count (P 5 0.028), with no differences concerning the neutrophil count, % BM blast, and the distribution of cytogenetic risk groups (P > 0.05). Chilean series depicted a lower overall survival (OS; 35 months vs. 56 months-Argentine; 55 monthsBrazil, P 5 0.030), which was consistent with a higher predominance of the high-risk group according both to the IPSS and IPSS-R (P 5 0.046 and P < 0.001). The IPSS-R system and its variables showed a good reproducibility to predict clinical outcome for the whole South-American population. Epidemiological and clinical characteristics, distribution among prognostic subgroups, the OS, and the access to disease modifying therapies were more similar between Argentinean and Brazilian compared with Chilean MDS series. This will need further analysis in a larger group of patients. Descriptive and comparative studies are necessary to establish epidemiological features useful for public health attitudes to generate suitable therapeutic schemes.

show abstract

“…2 This approach requires consensus regarding sample processing, antibody combinations and data analysis. The optimal methods for processing and handling samples for FC in MDS were previously published by the ELN Working Group in 2009 6 and are summarized in Table 2.…”

Section: Implementation Of Multiparameter Fc Analysis In Mdsmentioning

confidence: 99%

“…Analysis by flow cytometry (FC) of bone marrow cells has been introduced as an important co-criterion in the diagnosis of MDS. 2 FC can identify specific aberrations on both immature and maturing compartments among different hematopoietic lineages. The information obtained by FC analysis is moreover clearly complementary to cytomorphology.…”

Section: Introductionmentioning

confidence: 99%

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

et al. 2012

View full text Add to dashboard Cite

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

Cited by 447 publications

References 55 publications

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Myelodysplastic syndromes in South America: A multinational study of 1080 patients

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

Contact Info

Product

Resources

About